angiotensin-converting enzyme 2 candidate (vivoXPRESS platform) (AntoXa Corporation)

N/A

Report date: 2025/01/26 19:13:23

Base Information

Drug Nameangiotensin-converting enzyme 2 candidate (vivoXPRESS platform) (AntoXa Corporation)
Drug Alias NameCoronavirus spike glycoprotein inhibitor (vivoXPRESS platform) (AntoXa Corporation)
ClassificationBiologics > Protein drugs > Recombinant proteinBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionCoronavirus spike glycoprotein inhibitors
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAntoXa Corp
China Registration ClassN/A

Develop Information

Active CompaniesAntoXa Corp
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A